Karyotype Complexity and Prognosis in Acute Myeloid Leukemia

Overview

Journal Blood Cancer J

Date 2016 Jan 16

PMID 26771812

Citations 39

Authors

F Stolzel

B Mohr

M Kramer

U Oelschlagel

T Bochtler

W E Berdel

M Kaufmann

C D Baldus

K Schafer-Eckart

R Stuhlmann

H Einsele

S W Krause

H Serve

M Hanel

R Herbst

A Neubauer

K Sohlbach

J Mayer

J M Middeke

U Platzbecker

M Schaich

A Kramer

C Rollig

J Schetelig

M Bornhauser

G Ehninger

Affiliations

Soon will be listed here.

Abstract

A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p21∼22;q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with ⩾4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9;11)(p21∼22;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.

Citing Articles

Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.

Koolivand Z, Bahreini F, Rayzan E, Rezaei N Heliyon. 2025; 11(1):e41355.

PMID: 39811307 PMC: 11730532. DOI: 10.1016/j.heliyon.2024.e41355.

Direct Interaction Between CD34 Hematopoietic Stem Cells and Mesenchymal Stem Cells Reciprocally Preserves Stemness.

Safi R, Mohsen-Kanson T, Kouzi F, El-Saghir J, Dermesrobian V, Zugasti I Cancers (Basel). 2024; 16(23).

PMID: 39682159 PMC: 11640414. DOI: 10.3390/cancers16233972.

Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review).

Li J, Wang Y, Dong C, Luo L Int J Oncol. 2024; 65(6).

PMID: 39364739 PMC: 11542963. DOI: 10.3892/ijo.2024.5700.

High hyperdiploid karyotype with ≥ 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China.

Zhang Z, Fu C, Sun Y, Liu Y, Wang Q, Yan W Ann Hematol. 2024; 103(7):2337-2346.

PMID: 38849603 DOI: 10.1007/s00277-024-05834-5.

Identification of a Complex Karyotype Signature with Clinical Implications in AML and MDS-EB Using Gene Expression Profiling.

Lee C, Kim H, Kwon J, Hwang J, Park J, Shin O Cancers (Basel). 2023; 15(21).

PMID: 37958462 PMC: 10648390. DOI: 10.3390/cancers15215289.

References

Chilton L, Hills R, Harrison C, Burnett A, Grimwade D, Moorman A . Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. Leukemia. 2013; 28(2):321-8. DOI: 10.1038/leu.2013.198. View

Mohr B, Schetelig J, Schafer-Eckart K, Schmitz N, Hanel M, Rosler W . Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia. Br J Haematol. 2013; 161(2):237-44. DOI: 10.1111/bjh.12253. View

Cheson B, Bennett J, Kopecky K, Buchner T, Willman C, Estey E . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9. DOI: 10.1200/JCO.2003.04.036. View

Mrozek K, Marcucci G, Nicolet D, Maharry K, Becker H, Whitman S . Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012; 30(36):4515-23. PMC: 3518729. DOI: 10.1200/JCO.2012.43.4738. View

Middeke J, Beelen D, Stadler M, Gohring G, Schlegelberger B, Baurmann H . Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood. 2012; 120(12):2521-8. DOI: 10.1182/blood-2012-03-417972. View

Fang M, Storer B, Estey E, Othus M, Zhang L, Sandmaier B . Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood. 2011; 118(6):1490-4. PMC: 3156042. DOI: 10.1182/blood-2011-02-339721. View

Rollig C, Bornhauser M, Thiede C, Taube F, Kramer M, Mohr B . Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011; 29(20):2758-65. DOI: 10.1200/JCO.2010.32.8500. View

Schaich M, Rollig C, Soucek S, Kramer M, Thiede C, Mohr B . Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011; 29(19):2696-702. DOI: 10.1200/JCO.2010.33.7303. View

Stolzel F, Pfirrmann M, Aulitzky W, Kaufmann M, Bodenstein H, Bornhauser M . Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia. 2010; 25(3):420-8. DOI: 10.1038/leu.2010.279. View

10.

Medeiros B, Othus M, Fang M, Roulston D, Appelbaum F . Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010; 116(13):2224-8. PMC: 3709629. DOI: 10.1182/blood-2010-02-270330. View

11.

Rollig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhauser M . A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010; 116(6):971-8. DOI: 10.1182/blood-2010-01-267302. View

12.

Grimwade D, Hills R, Moorman A, Walker H, Chatters S, Goldstone A . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-65. DOI: 10.1182/blood-2009-11-254441. View

13.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

14.

Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-51. DOI: 10.1182/blood-2009-03-209262. View

15.

Breems D, van Putten W, de Greef G, van Zelderen-Bhola S, Gerssen-Schoorl K, Mellink C . Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008; 26(29):4791-7. DOI: 10.1200/JCO.2008.16.0259. View

16.

Mrozek K . Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol. 2008; 35(4):365-77. PMC: 3640813. DOI: 10.1053/j.seminoncol.2008.04.007. View

17.

Luquet I, Lai J, Barin C, Baranger L, Bilhou-Nabera C, Lippert E . Hyperdiploid karyotypes in acute myeloid leukemia define a novel entity: a study of 38 patients from the Groupe Francophone de Cytogenetique Hematologique (GFCH). Leukemia. 2007; 22(1):132-7. DOI: 10.1038/sj.leu.2404974. View

18.

Schetelig J, Schaich M, Schafer-Eckart K, Hanel M, Aulitzky W, Einsele H . Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Leukemia. 2014; 29(5):1060-8. DOI: 10.1038/leu.2014.335. View

19.

Slovak M, Kopecky K, Cassileth P, Harrington D, Theil K, Mohamed A . Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96(13):4075-83. View